267 related articles for article (PubMed ID: 32493217)
1. Cardiotoxicity evaluation using magnetic resonance imaging in breast Cancer patients (CareBest): study protocol for a prospective trial.
Hong YJ; Kim GM; Han K; Kim PK; Lee SA; An E; Lee JY; Lee HJ; Hur J; Kim YJ; Kim MJ; Choi BW
BMC Cardiovasc Disord; 2020 Jun; 20(1):264. PubMed ID: 32493217
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up.
Giusca S; Korosoglou G; Montenbruck M; Geršak B; Schwarz AK; Esch S; Kelle S; Wülfing P; Dent S; Lenihan D; Steen H
Circ Cardiovasc Imaging; 2021 Jun; 14(6):e012459. PubMed ID: 34126756
[TBL] [Abstract][Full Text] [Related]
3. Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial.
Antunes P; Esteves D; Nunes C; Sampaio F; Ascensão A; Vilela E; Teixeira M; Amarelo AL; Joaquim A
Trials; 2019 Jul; 20(1):433. PubMed ID: 31307527
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal assessment of right ventricular structure and function by cardiovascular magnetic resonance in breast cancer patients treated with trastuzumab: a prospective observational study.
Barthur A; Brezden-Masley C; Connelly KA; Dhir V; Chan KK; Haq R; Kirpalani A; Barfett JJ; Jimenez-Juan L; Karur GR; Deva DP; Yan AT
J Cardiovasc Magn Reson; 2017 Apr; 19(1):44. PubMed ID: 28395671
[TBL] [Abstract][Full Text] [Related]
5. Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.
Howden EJ; Bigaran A; Beaudry R; Fraser S; Selig S; Foulkes S; Antill Y; Nightingale S; Loi S; Haykowsky MJ; La Gerche A
Eur J Prev Cardiol; 2019 Feb; 26(3):305-315. PubMed ID: 30376366
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal assessment of concurrent changes in left ventricular ejection fraction and left ventricular myocardial tissue characteristics after administration of cardiotoxic chemotherapies using T1-weighted and T2-weighted cardiovascular magnetic resonance.
Jordan JH; D'Agostino RB; Hamilton CA; Vasu S; Hall ME; Kitzman DW; Thohan V; Lawrence JA; Ellis LR; Lash TL; Hundley WG
Circ Cardiovasc Imaging; 2014 Nov; 7(6):872-9. PubMed ID: 25273568
[TBL] [Abstract][Full Text] [Related]
8. Cardiac MRI Myocardial Functional and Tissue Characterization Detects Early Cardiac Dysfunction in a Mouse Model of Chemotherapy-Induced Cardiotoxicity.
Naresh NK; Misener S; Zhang Z; Yang C; Ruh A; Bertolino N; Epstein FH; Collins JD; Markl M; Procissi D; Carr JC; Allen BA
NMR Biomed; 2020 Sep; 33(9):e4327. PubMed ID: 32567177
[TBL] [Abstract][Full Text] [Related]
9. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study.
Gong IY; Ong G; Brezden-Masley C; Dhir V; Deva DP; Chan KKW; Graham JJ; Chow CM; Thavendiranathan P; Dai D; Ng MY; Barfett JJ; Connelly KA; Yan AT
Int J Cardiovasc Imaging; 2019 Apr; 35(4):653-662. PubMed ID: 30390170
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular magnetic resonance characterization of myocardial tissue injury in a miniature swine model of cancer therapy-related cardiovascular toxicity.
Nakata K; Kucukseymen S; Cai X; Yankama T; Rodriguez J; Sai E; Pierce P; Ngo L; Nakamori S; Tung N; Manning WJ; Nezafat R
J Cardiovasc Magn Reson; 2024 Summer; 26(1):101033. PubMed ID: 38460840
[TBL] [Abstract][Full Text] [Related]
11. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
[TBL] [Abstract][Full Text] [Related]
12. Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Tahir E; Azar M; Shihada S; Seiffert K; Goy Y; Beitzen-Heineke A; Molwitz I; Muellerleile K; Stehning C; Schön G; Adam G; Petersen C; Müller V; Lund GK
Eur Radiol; 2022 Mar; 32(3):1853-1865. PubMed ID: 34536111
[TBL] [Abstract][Full Text] [Related]
13. Cardiac magnetic resonance imaging-based myocardial strain study for evaluation of cardiotoxicity in breast cancer patients treated with trastuzumab: A pilot study to evaluate the feasibility of the method.
Nakano S; Takahashi M; Kimura F; Senoo T; Saeki T; Ueda S; Tanno J; Senbonmatsu T; Kasai T; Nishimura S
Cardiol J; 2016; 23(3):270-80. PubMed ID: 27173679
[TBL] [Abstract][Full Text] [Related]
14. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
[TBL] [Abstract][Full Text] [Related]
15. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study.
Dhir V; Yan AT; Nisenbaum R; Sloninko J; Connelly KA; Barfett J; Haq R; Kirpalani A; Chan KKW; Petrella TM; Brezden-Masley C
Int J Cardiovasc Imaging; 2019 Nov; 35(11):2085-2093. PubMed ID: 31197526
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance.
Huang H; Nijjar PS; Misialek JR; Blaes A; Derrico NP; Kazmirczak F; Klem I; Farzaneh-Far A; Shenoy C
J Cardiovasc Magn Reson; 2017 Mar; 19(1):34. PubMed ID: 28335788
[TBL] [Abstract][Full Text] [Related]
17. Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.
Jordan JH; Vasu S; Morgan TM; D'Agostino RB; Meléndez GC; Hamilton CA; Arai AE; Liu S; Liu CY; Lima JA; Bluemke DA; Burke GL; Hundley WG
Circ Cardiovasc Imaging; 2016 Aug; 9(8):. PubMed ID: 27502058
[TBL] [Abstract][Full Text] [Related]
18. Assessment of Feasibility and Interscan Variability of Short-time Cardiac MRI for Cardiotoxicity Evaluation in Breast Cancer.
Hong YJ; Han K; Lee HJ; Hur J; Kim YJ; Kim MJ; Choi BW
Radiol Cardiothorac Imaging; 2024 Feb; 6(1):e220229. PubMed ID: 38329404
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
20. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity.
Nabati M; Janbabai G; Baghyari S; Esmaili K; Yazdani J
J Cardiovasc Pharmacol; 2017 May; 69(5):279-285. PubMed ID: 28141699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
